Posted by Michael Wonder on 04 Feb 2020
Seqirus announces U.S. FDA approval of its first-ever adjuvanted, cell-based pandemic influenza A (H5N1) vaccine
3 February 2020 - Seqirus, a global leader in influenza prevention and pandemic response, today announced that the U.S. FDA has approved Audenz (influenza A (H5N1) monovalent vaccine, adjuvanted) to help protect individuals six months of age and older against influenza A (H5N1)
Audenz is the first-ever adjuvanted, cell-based influenza vaccine designed to protect against influenza A (H5N1) in the event of a pandemic.
The novel vaccine combines two leading-edge technologies—MF59 adjuvant and cell-based antigen manufacturing. AUDENZ is designed to be rapidly deployed to help protect the U.S. population and can be stockpiled for first responders in the event of pandemic.
